"By the middle of next year or this time next year, it will be clear to people even outside the movement disorder community that this is a powerhouse center." —Steven J. Frucht, MD
December 2017
Advertisement
Advertisement
Trending on HCPLive
1
Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD
2
Phase 3 Dermatomyositis Trial Sees Brepocitinib Meet Primary Endpoint
3
Q&A: Fear, Not Appetite Loss, Drives ARFID Eating Patterns in Food Allergy
4
European Society of Cardiology 2026 Preview: 6 Trials to Know
5